Cite

HARVARD Citation

    Du, C. et al. (2020). 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. Leukemia & lymphoma. 61 (5), pp. 1201-1210. [Online]. 
  
Back to record